686 related articles for article (PubMed ID: 26705122)
21. Multiple Sclerosis.
Yamout BI; Alroughani R
Semin Neurol; 2018 Apr; 38(2):212-225. PubMed ID: 29791948
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
Esposito F; Ferrè L; Clarelli F; Rocca MA; Sferruzza G; Storelli L; Radaelli M; Sangalli F; Moiola L; Colombo B; Martinelli Boneschi F; Comi G; Filippi M; Martinelli V
J Neurol; 2018 Apr; 265(4):896-905. PubMed ID: 29435643
[TBL] [Abstract][Full Text] [Related]
23. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Kappos L; De Stefano N; Freedman MS; Cree BA; Radue EW; Sprenger T; Sormani MP; Smith T; Häring DA; Piani Meier D; Tomic D
Mult Scler; 2016 Sep; 22(10):1297-305. PubMed ID: 26585439
[TBL] [Abstract][Full Text] [Related]
24. "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.
Giovannoni G; Tomic D; Bright JR; Havrdová E
Mult Scler; 2017 Aug; 23(9):1179-1187. PubMed ID: 28381105
[TBL] [Abstract][Full Text] [Related]
25. No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy.
Damasceno A; Damasceno BP; Cendes F
Mult Scler; 2016 Jan; 22(1):64-72. PubMed ID: 26432855
[TBL] [Abstract][Full Text] [Related]
26. Established and novel disease-modifying treatments in multiple sclerosis.
Cross AH; Naismith RT
J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
[TBL] [Abstract][Full Text] [Related]
27. What does first-line therapy mean for paediatric multiple sclerosis in the current era?
Hacohen Y; Banwell B; Ciccarelli O
Mult Scler; 2021 Nov; 27(13):1970-1976. PubMed ID: 32633605
[TBL] [Abstract][Full Text] [Related]
28. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.
Wattjes MP; Rovira À; Miller D; Yousry TA; Sormani MP; de Stefano MP; Tintoré M; Auger C; Tur C; Filippi M; Rocca MA; Fazekas F; Kappos L; Polman C; Frederik Barkhof ; Xavier Montalban ;
Nat Rev Neurol; 2015 Oct; 11(10):597-606. PubMed ID: 26369511
[TBL] [Abstract][Full Text] [Related]
29. Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
Uher T; Havrdova E; Sobisek L; Krasensky J; Vaneckova M; Seidl Z; Tyblova M; Ramasamy D; Zivadinov R; Horakova D
Mult Scler; 2017 Feb; 23(2):242-252. PubMed ID: 27230790
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.
Nandoskar A; Raffel J; Scalfari AS; Friede T; Nicholas RS
Drugs; 2017 May; 77(8):885-910. PubMed ID: 28429241
[TBL] [Abstract][Full Text] [Related]
31. Visual field impairment captures disease burden in multiple sclerosis.
Ortiz-Perez S; Andorra M; Sanchez-Dalmau B; Torres-Torres R; Calbet D; Lampert EJ; Alba-Arbalat S; Guerrero-Zamora AM; Zubizarreta I; Sola-Valls N; Llufriu S; Sepúlveda M; Saiz A; Villoslada P; Martinez-Lapiscina EH
J Neurol; 2016 Apr; 263(4):695-702. PubMed ID: 26860093
[TBL] [Abstract][Full Text] [Related]
32. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
33. Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
Filippi M; Amato MP; Centonze D; Gallo P; Gasperini C; Inglese M; Patti F; Pozzilli C; Preziosa P; Trojano M
J Neurol; 2022 Oct; 269(10):5382-5394. PubMed ID: 35608658
[TBL] [Abstract][Full Text] [Related]
34. [Is MRI monitoring useful in clinical practice in patients with multiple sclerosis? Yes].
Brochet B
Rev Neurol (Paris); 2013 Nov; 169(11):858-63. PubMed ID: 24094530
[TBL] [Abstract][Full Text] [Related]
35. Conventional and advanced MRI in multiple sclerosis.
Louapre C
Rev Neurol (Paris); 2018 Jun; 174(6):391-397. PubMed ID: 29784248
[TBL] [Abstract][Full Text] [Related]
36. Impact of diagnosis and early treatment on the course of multiple sclerosis.
Noyes K; Weinstock-Guttman B
Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
[TBL] [Abstract][Full Text] [Related]
37. Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems.
Habibi M; Kuttab HM
Am J Health Syst Pharm; 2016 Jun; 73(11):811-9. PubMed ID: 27126827
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
J Clin Neurosci; 2014 Nov; 21(11):1847-56. PubMed ID: 24986155
[TBL] [Abstract][Full Text] [Related]
39. NEDA treatment target? No evident disease activity as an actionable outcome in practice.
Parks NE; Flanagan EP; Lucchinetti CF; Wingerchuk DM
J Neurol Sci; 2017 Dec; 383():31-34. PubMed ID: 29246616
[TBL] [Abstract][Full Text] [Related]
40. 'No evidence of disease activity' - is it an appropriate surrogate in multiple sclerosis?
Hegen H; Bsteh G; Berger T
Eur J Neurol; 2018 Sep; 25(9):1107-e101. PubMed ID: 29687559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
